Dummer R, Corrie P, Gutzmer R, Meniawy TM, et al. First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. J Clin Oncol 2023 Jun 12:JCO2202199. doi: 10.1200/JCO.22.02199.
PMID: 37307514